Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
03/2000
03/09/2000WO2000012084A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000WO2000012067A1 Novel pharmaceutical salt form
03/09/2000WO2000012049A2 A method for the treatment of staphylococcal disease
03/09/2000WO2000012018A1 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
03/09/2000WO1999020260A3 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
03/09/2000DE19838809A1 Trockenextrakt aus der Hennapflanze, Verfahren zu dessen Herstellung und dessen Verwendung Dry extract of the henna plant, process for its preparation and its use
03/09/2000CA2633074A1 Elongase genes and uses thereof
03/09/2000CA2435050A1 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
03/09/2000CA2342250A1 Quinazoline derivatives as medicaments
03/09/2000CA2342230A1 2-oxo-2h-quinoline derivatives
03/09/2000CA2342222A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000CA2342109A1 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
03/09/2000CA2341775A1 Inducible expression system
03/09/2000CA2341754A1 Stem cells bearing an fgf receptor on the cell surface
03/09/2000CA2341699A1 A method for the treatment of staphylococcal disease
03/09/2000CA2341612A1 Indazole derivatives with 5-ht2 receptor activity
03/09/2000CA2341525A1 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
03/09/2000CA2341522A1 Novel pharmaceutical salt form
03/09/2000CA2341308A1 Human latent transforming growth factor-.beta. binding protein 3
03/09/2000CA2340648A1 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
03/08/2000EP0983373A1 Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid
03/08/2000EP0983346A2 Short peptides which selectively modulate the activity of serine/threonine kinases
03/08/2000EP0983304A1 Dermatan disulfate, an inhibitor of thrombin generation and complement activation
03/08/2000EP0983301A2 Thrombin-inhibiting peptide
03/08/2000EP0983267A1 Amidoaromatic ring sulfonamide hydroxamic acid compounds
03/08/2000EP0983260A2 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
03/08/2000EP0983258A1 N-hydroxy 4-sulfonyl butanamide compounds
03/08/2000EP0983257A1 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
03/08/2000EP0983105A1 Method of removing thrombosis in fistulae
03/08/2000EP0983082A1 Novel administration of thrombopoietin
03/08/2000EP0983078A1 SIALOADHESIN FAMILY 4 cDNA
03/08/2000EP0591355B1 Porphycene compounds for photodynamic therapy
03/08/2000CN1246857A Substituted pyrimidinone and pyridinone compounds and their use
03/08/2000CN1246848A 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
03/08/2000CN1246847A Nitrogen containing heteroaromatics as factor Xa inhibitors
03/08/2000CN1246778A Method and compositions for producing dried, storage-stable platelets
03/08/2000CN1246365A Mongolian medicine for treating internal hemorrhage
03/08/2000CN1050132C Ginkgotide derivatives
03/07/2000US6034231 Human CNP gene and precursor protein
03/07/2000US6034222 Method for the separation of recombinant pro-factor IX from recombinant factor IX
03/07/2000US6034221 Reduced side effects
03/07/2000US6034215 3-amino-2-oxo-1-piperidnercetic derivatives as enzyme inhibitors
03/07/2000US6034127 Amidino protease inhibitors
03/07/2000US6034112 Use of flupirtine the prophylaxis and therapy of diseases associated with an impairment of the hematopoetic cell system
03/07/2000US6034111 Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
03/07/2000US6034104 Anticoagulant agents
03/07/2000US6034103 Benzamidine derivatives and their use as anti-coagulants
03/07/2000US6034094 Pharmaceutically useful 3,4-dihydroisoquinoline
03/07/2000US6034084 Thio acid derived monocyclic N-heterocyclics as anticoagulants
03/07/2000US6034067 Serine protease inhibitors
03/07/2000US6034060 Peptide having an ability to promote the activation of protein C by thrombin
03/07/2000US6033667 Method for detecting the presence of P-selectin
03/02/2000WO2000011171A2 Human rna-associated proteins
03/02/2000WO2000011170A1 14400 receptor, a g-protein coupled receptor
03/02/2000WO2000011033A2 Expression and export of angiostatin and endostatin as immunofusins
03/02/2000WO2000010993A1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
03/02/2000WO2000010982A1 Quinazoline derivatives and pharmaceutical applications therof
03/02/2000WO2000010968A2 Novel aryl sulphonamide amino acid esters and analogues
03/02/2000WO2000010967A1 Novel aryl sulphonamides and analogues
03/02/2000WO2000010609A1 Targeting of molecules to large vessel endothelium using epcr
03/02/2000WO2000010601A1 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
03/02/2000WO2000010563A1 Novel substituted triazole compounds
03/02/2000WO2000010385A1 Method of enhancing catheter patency using a citrate salt catheter lock solution
03/02/2000WO1999060126A3 Protein z-dependent protease inhibitor
03/02/2000WO1999058642A3 Secreted proteins and polynucleotides encoding them
03/02/2000DE19839499A1 2-Oxo-2H-chinolinderivate 2-oxo-2H-quinoline
03/02/2000DE19839337A1 Parenteral medicament for treating antithrombin III deficiency contains potent beta-isoform of antithrombin III
03/02/2000DE19838705A1 Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one New dihydro- (1,2,3) triazolo [4,5-d] pyrimidin-7-one
03/02/2000CA2341586A1 Targeting of molecules to large vessel endothelium using epcr
03/02/2000CA2341370A1 Novel substituted triazole compounds
03/02/2000CA2341357A1 Quinazoline derivatives and pharmaceutical applications therof
03/02/2000CA2341028A1 Novel aryl sulphonamide amino acid esters and analogues
03/02/2000CA2340928A1 Novel arylsulphonamides and analogues
03/02/2000CA2340466A1 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
03/02/2000CA2340457A1 14400 receptor, a g-protein coupled receptor
03/02/2000CA2340277A1 Human rna-associated proteins
03/01/2000EP0982297A2 Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
03/01/2000EP0981529A1 A new process for the preparation of a pharmacologically active substance
03/01/2000EP0981521A2 Novel macrocyclic compounds as metalloprotease inhibitors
03/01/2000EP0618926B1 New peptide derivatives
03/01/2000CN1245799A Preparation method of pyrrolidyl hydroxamic acid compound
03/01/2000CN1245719A Antithrombosis medicine using inactive insuline as skeleton and containing arginine-glycine-aspartic acid sequence
02/2000
02/29/2000US6031135 Protein kinase-c activity; antitumor agents, antiinflammatory agents, preservatives; treating thrombosis
02/29/2000US6031114 Process for pyrrolidinyl hydroxamic acid compounds
02/29/2000US6031081 Process for reactivating purified membrane proteins by freezing them
02/29/2000US6030989 Hemoregulatory compounds
02/29/2000US6030985 Stroke, schizophrenia, antianxiolytic and antihypoxia agents, analgesics; neurodegenerative disorders, e.g., nerve degeneration and/or necrosis; hyperglycemic, antiepileptic and antiinflammatory agents; drug abuse;
02/29/2000US6030972 2- or 5-aminomethyl,2- or 5-cyanopyrimidines as intermediates of anticoagulants in extracorporeal circulation (heart-lung machine, hemodialysis)
02/29/2000US6030961 Oxyalkylene phosphate compounds and uses thereof
02/29/2000US6030835 Methods and composition for identifying group a streptococcus
02/29/2000US6030812 Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
02/28/2000CA2281055A1 Antithrombin iii-beta-comprising pharmaceutical preparation
02/24/2000WO2000009713A1 Adenoviral vectors encoding erythropoietin and their use in gene therapy
02/24/2000WO2000009690A1 Extracellular adhesive proteins, exadh1 and exadh2
02/24/2000WO2000009552A1 Secreted proteins and polynucleotides encoding them
02/24/2000WO2000009542A1 SERINE PROTEASE INHIBITORS COMPRISING α-KETO HETEROCYCLES
02/24/2000WO2000009540A1 Purification of blood clotting proteins
02/24/2000WO2000009537A2 Compounds having growth hormone releasing activity
02/24/2000WO2000009496A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
02/24/2000WO2000009480A1 Novel sulfonyl derivatives
1 ... 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 ... 671